Lessons from a modern-day pandemic: redesigning the pharmaceutical supply chain, a Manufacturing Chemist featured story

Considering the unprecedented scope of the current pandemic, all aspects of pharmaceutical supply chain contingency planning have, so far, delivered as expected. To date, only a single drug shortage has been reported (except for COVID-19-driven demand for hydroxychloroquine, for example).

Safety stocks across the pharmaceutical manufacturing network and warehouses have kicked in and supply to pharmacies remains uninterrupted. This will not be indefinite and, should the lockdown extend further, one can expect a cascade of drug shortages. Nonetheless, to this date, the system has proven to be resilient and able to cope with a severe healthcare crisis.

Click here to view the article.